Differentiating factors in treatment-free remission trials: impact of study design on results and clinical applications

References

• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
   PubMed Web of Science ®Google Scholar
• Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305.
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study. Blood. 2013;122:515–522.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–430.
   PubMed Web of Science ®Google Scholar
• Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101:717–723.
   PubMed Web of Science ®Google Scholar
• Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90:910–914.
   PubMed Web of Science ®Google Scholar
• Mori S, le Coutre PD, Abruzzese E, et al. Imatinib Suspension and Validation study: results from the ISAV study at 62 months [abstract]. Blood. 2017;130. [abstract 2870].
   Web of Science ®Google Scholar
• Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–757.
   PubMed Web of Science ®Google Scholar
• Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846–854.
   PubMed Web of Science ®Google Scholar
• Ross DM, Masszi T, Gomez-Casares MT, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018;144:945–954.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Boquimpani C, Kim DW, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168:461–470.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Nishiwaki K, Nakaseko C, et al. Successful treatment free remission in CML after 2 year consolidation with nilotinib of an MR4.5 response level achieved originally with imatinib treatment: first report from STAT2 trial in Japan [abstract]. Haematologica. 2016;101. [abstract P229].
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Kawaguchi T, Kuroda J, et al. Discontinuation of nilotinib in patients with chronic myeloid leukemia who have maintained deep molecular responses for at least 2 years: a multicenter phase 2 Stop Nilotinib (NILSt) trial [abstract]. Blood. 2016;128. [abstract 790].
   PubMed Web of Science ®Google Scholar
• Okada M, Imagawa J, Tanaka H, et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk. 2018;18:353–360.e1.
   PubMed Web of Science ®Google Scholar
• Shah NP, Gutiérrez VG, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DASFREE) [abstract]. Blood. 2017;130. [abstract 314].
   Google Scholar
• Kumagai T, Nakaseko C, Nishiwaki K, et al. Discontinuation of dasatinib after deep molecular response for over 2 years in patients with chronic myelogenous leukemia and the unique profiles of lymphocyte subsets for successful discontinuation: a prospective, multicenter Japanese trial (D-STOP Trial) [abstract]. Blood. 2016;128. [abstract 791].
   Web of Science ®Google Scholar
• Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4:e310–e316.
   PubMed Web of Science ®Google Scholar
• Clark R, Polydoros F, Apperley J, et al. Initial reduction of therapy before complete withdrawal improves the chance of successful treatment discontinuation in chronic myeloid leukemia (CML): year 2 results in the British DESTINY study [abstract]. Haematologica. 2017;102. [abstract S423].
   Web of Science ®Google Scholar
• Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–1531.
   PubMed Web of Science ®Google Scholar
• Richter J, Söderlund S, Lübking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821–2823.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. 2016; V1.2017.
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. 2018; V1.2019.
   Google Scholar
• FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response [Internet]. [cited 2018 August 17]; Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm590391.htm.
   Google Scholar
• Clinical Trials.gov [Internet]. [cited 2018 May 10]. Available from: https://clinicaltrials.gov/.
   Google Scholar
• UMIN clinical trials registry [Internet]. [cited 2018 May 10]. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006983.
   Google Scholar
• Baccarani M. Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence. Leukemia. 2017;31:1015–1016.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. 2018; V4.2018.
   Google Scholar
• Lee SE, Choi SY, Bang JH, et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol. 2013;88:449–454.
   PubMed Web of Science ®Google Scholar
• Mahon F, Boquimpani CM, Takahashi N, et al. Patient-reported quality of life before and after stopping treatment in the ENESTop trial of treatment-free remission for patients with chronic myeloid leukemia in chronic phase [abstract]. Blood. 2016;128. [abstract 1891].
   Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. 2015; V1.2016.
   Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• Saußele S, Richter J, Hochhaus A, et al. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–1647.
   PubMed Web of Science ®Google Scholar
• Dulucq S, Mahon FX. Deep molecular responses for treatment-free remission in chronic myeloid leukemia. Cancer Med. 2016;5:2398–2411.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17–23.
   PubMed Web of Science ®Google Scholar